-
Mashup Score: 0Letermovir prevents cytomegalovirus (CMV) in transplant patients - 4 year(s) ago
Per Ljungman, MD, PhD, Karolinska Institutet, Stockholm, Sweden, highlights the successful use of letermovir, a DNA terminase complex inhibitor, as…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Spain & COVID-19: HSCT, CAR-T and clinical practice - 4 year(s) ago
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses how hematopoietic stem cell transplants (HSCT) in Spain have…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Transplantation, COVID-19 & Brazil - 4 year(s) ago
Dr Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil, discusses hematological changes as a result of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0B-T cell interactions in GvHD - 4 year(s) ago
Sara Deola, MD, PhD, Sidra Medicine, Doha, Qatar, outlines interactions between B- and T-cells in graft-versus-host disease (GvHD), and discusses…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, discusses the efficacy of haploidentical stem cell…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PET/CT in multiple myeloma monitoring - 4 year(s) ago
Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the prognostic value of positron emission tomography/computer tomography (PET/CT) in…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1AML relapse after HSCT: trends and predictive factors - 4 year(s) ago
Ali Bazarbachi, MD, PhD, of the American University of Beirut-Medical Center, Beirut, Lebanon, outlines the trends and predictive factors for…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0EBMT 2020: cellular therapy day - 4 year(s) ago
Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, discusses cellular therapy, specifically the engineering of T-cells and the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New SLAMF7-targeted CAR T-cell therapy - 4 year(s) ago
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Hermann Einsele, University Hospital of Würzburg, Würzburg, DE, about chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1TA-TMA: an increasingly identified complication post-transplant - 4 year(s) ago
Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses thrombotic microangiopathy (TMA), specifically highlighting transplant-associated TMA (TA-TMA). TA-TMA is…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
VIDEO: Letermovir prevents cytomegalovirus (CMV) in transplant patients w/ Per Ljungman @karolinskainst: https://t.co/J3tlmblbSc @TheEBMT #EBMT20Virtual @OncoAlert #OncoAlert #HemOnc #BMTsm https://t.co/6Jl1HFalfH